Open AccessLittle Impact of Antiplatelet Agents on Venous Thromboembolism after Hip Fracture Surgery
Author(s) -
Hyung Min Ji,
Yong Seuk Lee,
YongChan Ha,
Ki Choul Kim,
Kyung Hoi Koo
Publication year - 2011
Publication title -
journal of korean medical science/journal of korean medical science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.743
H-Index - 66
eISSN - 1598-6357
pISSN - 1011-8934
DOI - 10.3346/jkms.2011.26.12.1625
Subject(s) - medicine , aspirin , incidence (geometry) , pulmonary embolism , deep vein , stroke (engine) , hip fracture , thrombosis , surgery , logistic regression , venous thrombosis , platelet aggregation inhibitor , osteoporosis , mechanical engineering , physics , optics , engineering
Since the late 1980s, low dose aspirin has been used to prevent stroke and ischemic heart disease. However, prophylactic effect of antiplatelets against venous thromboembolism (VTE), in patients who undergo hip fracture surgery (HFS) is controversial. Our purpose was to determine the incidence of symptomatic VTE after HFS and to evaluate whether antiplatelets reduce the development of symptomatic VTE following HFS. We retrospectively reviewed 858 HFS in 824 consecutive patients which were performed from May 2003 to April 2010 at an East Asian institute. We compared the incidence of symptomatic VTE in antiplatelet users and non-users using multivariate logistic regression analyses. Overall incidences of symptomatic pulmonary embolism including fatal pulmonary embolism, and symptomatic deep vein thrombosis in this study were 2.4% (21/858), and 3.5% (30/858), respectively. The incidence of symptomatic VTE was 4.8% (12/250) in antiplatelet users and 4.3% (26/608) in non-users (P = 0.718). It is suggested that antiplatelet agents are not effective in prevention of symptomatic VTE after HFS.